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Abstract Assessment of ALK gene rearrangements is strongly recommended by the
Molecular Testing Guideline for Selection of Lung Cancer Patients proposed by IASLC,
AMP, and CAP at the time of diagnosis for patients with advanced stage disease. Non-
small-cell lung cancer (NSCLC) with ALK gene rearrangements or the resulting fusion pro-
teins have been, for the most part, successfully targeted with ALK tyrosine kinase inhibitors
(TKIs). The most frequent rearrangement, the EML4-ALK oncogenic fusion, has more than
10 distinct variants, eachwith a discrete breakpoint in EML4. Recent studies have suggested
that EML4-ALK variants may have differential responses to TKIs. Additionally, non-EML4-
ALK fusions that result from ALK rearrangements with diverse 5′ partners could possibly
have varied biologic and clinical implications in their therapeutic responses and outcomes
of patients with NSCLC. Existing literature documents at least 20 non-EML4 fusion partners
for ALK, and the clinical responsiveness to crizotinib ranges from increased sensitivity to re-
sistance. This underscores the importance of identifying the precise 5′ fusion partner to ALK
before initiation of therapy. Herein we report the identification of a novel SLMAP-ALK fusion
in a patient with NSCLC.
[Supplemental material is available for this article.]
CASE PRESENTATION
A 73-yr-old man, a former smoker, was found to have a right lower lobe spiculated mass with
adjacent peribronchovascular soft tissue thickening (Fig. 1A) that was noted incidentally on
MRI of his abdomen to monitor a previously diagnosed pancreatic intraductal papillary mu-
cinous neoplasm. Subsequent PETCT showed a large, FDG-avidmass in the right lower lobe
measuring 4.1 cm in its greatest dimension and no evidence of metastatic lesions.
The patient then underwent video-assisted thoracoscopic surgery (VATS) resection of the
right lower lobe with lymph node resection. Surgical resection showed pathology of a stage
IIA (pT2bN1) lung adenocarcinoma, measuring 6.0 cm, acinar predominant with papillary
and micropapillary features (Fig. 1B). One lobar lymph node was positive for metastatic car-
cinoma, and one lymph node was involved by direct extension of tumor. ALK D5F3 clone
immunohistochemistry (IHC) was performed on the lung specimen and showed diffuse gran-
ular cytoplasmic staining (Fig. 1C). The tumor was negative for p40 and focally positive for
TTF-1 by IHC.
An ALK rearrangement detected using Anchored Multiplex PCR (AMP) technology was
confirmed by fluorescence in situ hybridization (FISH) with the ALK (2p23) break-apart probe
(Fig. 1D). The patient was started on adjuvant chemotherapy: cisplatin and pemetrexed for
four cycles. RNA analysis was performed on formalin-fixed paraffin-embedded (FFPE) tissue
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and revealed a novel fusion of SLMAP and ALK. Two different breakpoints in SLMAP, yield-
ing two transcripts (exon 11 and exon 12) were fused with the canonical ALK breakpoint
(exon 20), retaining the tyrosine kinase domain (Childress et al. 2018). After chemotherapy
the patient was enrolled in a clinical trial (ALCHEMIST) and received treatment with crizoti-
nib. Clinical and radiological follow-up has shown no evidence of recurrent or metastatic dis-
ease more than 2 yr after surgery.
Figure 1. (A) CT image showing a right lower lobe spiculated lung mass with soft tissue thickening (arrow). (B)
Hematoxylin and eosin (H&E)-stained tissue showing lung adenocarcinoma, acinar predominant with papillary
and micropapillary features. (C ) Immunostaining for ALK D5F3 with strong granular cytoplasmic staining. (D)
Positive fluorescence with ALK break-apart probe is represented with split red and green signals. Cells nega-
tive for the rearrangement show fused yellow signal. (E) Novel SLMAP-ALK fusions with two different break-
points in SLMAP, yielding two transcripts (E12:E20 SLMAP-ALK and E13:E20 SLMAP-ALK) fused with the
canonical breakpoint (exon 20) of the ALK gene. (Figure and legend continue on following page.)
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TECHNICAL ANALYSIS
DNA extraction from FFPE resection tissue was performed following the manufacturer’s pro-
tocol using DNeasy Tissue kit on the QIAcube (QIAGEN). The extracted DNAwas subjected
to library preparation and targeted next-generation sequencing (NGS) using the TruSeq
Amplicon—Cancer Panel on the MiSeq (illumina). Variant analysis was performed with the
NextGENe software v2.4 (SoftGenetics, LLC).
RNA from the same FFPE resection tissue was extracted using the ALLPrep DNA/RNA kit
(QIAGEN). RNA fusions were detected with a custom panel targeting 17 genes involved in
cancer, using Archer’s Anchored Multiplex PCR (AMP) NGS-based technology (ArcherDx).
Briefly, after preparation of cDNA with random priming, the library is subject to a cDNA
Figure 1. (Continued.) (F ) JBrowse view of the SLMAP-ALK fusion. (G) Electropherogram from Sanger se-
quencing showing both SLMAP-ALK transcripts with the junctional sequence. Primers used are in
Supplemental Table S1.
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quality check using a quantitative PCR (qPCR) assay that uses SYBR green to quantify frag-
ments available for downstream amplification and library preparation. AMP chemistry then
uses molecular barcodes along with universal primer binding sites to ligate with the dou-
ble-stranded cDNA library for selection of fragments with known and novel fusion partners.
Subsequent annealing with gene-specific primers that target the 17 genes in the fusion pan-
el leads to PCR amplification of the fusion product. The resulting NGS library is sequenced
on theMiSeq. Identification of fusion transcripts, exons, and breakpoints was performedwith
the Archer Analysis software v5.1.2 (ArcherDx). Novel fusions detected were confirmed by rt-
PCR and Sanger sequencing of the product using BIgDye Terminators on the ABI3130
(Thermo Fisher Scientific).
ALK IHC was performed with ALK D3F5 Ventana CDx Assay (Roche Diagnostics GmbH)
and FISH, using an ALK (2p23) break-apart probe (Abbott Molecular).
GENOMIC ANALYSIS
A novel ALK fusion was identified in the RNA that was analyzed using AMP technology. The
transcript (Table 1; Fig. 1E) demonstrated a 5′ SLMAP fusion with 3′ ALK. Details of the break-
points showed that there were likely two isoforms of the fusion—E12:E20 SLMAP-ALK and
E13:E20 SLMAP-ALK. Both isoforms were in-frame and exceeded the quality control require-
ments for a confident fusion call. These included a minimum of three start sites, five reads
spanning the junction and 10% of total reads (#/%) as indicated in Figure 1E. The E12:E20
SLMAP-ALK fusion was clearly seen in the JBrowse viewer (Fig. 1F). Exon-specific primers
that were selected and synthesized were able to correctly identify and confirm the fusion
junctions of both—E12:E20 SLMAP-ALK and E13:E20 SLMAP-ALK—isoforms (Fig. 1G).
No clinically relevant DNA variants were detected in the genes targeted by the TruSeq
Amplicon—Cancer NGS Panel.
VARIANT INTERPRETATION
Molecular testing is critical in the management of advanced lung cancer. Prior knowledge of
the ALK fusion partner has an impact on the efficacy of ALK TKIs. In vitro studies have sug-
gested that different EML4-ALK fusion transcripts show varied susceptibility to crizotinib
(Heukman et al. 2012). Yoshida et al. (2016) have further documented differential clinical im-
pact of ALK fusion variants to crizotinib in patients. Some partners lead to primary resistance
to crizotinib, and some partners might predict efficacy of ALK TKIs other than EML4 in
Table 1. Details for the two fusion transcripts found in the patient


























Novel targetable ALK fusion in lung adenocarcinoma
C O L D S P R I N G H A R B O R
Molecular Case Studies
Pagan et al. 2019 Cold Spring Harb Mol Case Stud 5: a003939 4 of 6
 Cold Spring Harbor Laboratory Press on June 13, 2019 - Published by molecularcasestudies.cshlp.orgDownloaded from 
advanced ALK-positive NSCLCs (Kang et al. 2018). Guidelines for ALK testing recommend
testing and include either ALK IHC or FISH. However, these methods do not identify or dis-
tinguish from any of the many ALK partners. The AMP technology is able to detect novel
RNA fusions in tumors. To the best of our knowledge, this is the first time a fusion of
SLMAP and ALK has been reported in a solid or hematologic malignancy.
Patients with ALK fusion positive lung adenocarcinoma are generally younger and have
either none or a light smoking history. These lung tumors have also been reported to more
frequently show signet ring cell morphology (Pareja et al. 2015). This patient’s age, smoking
history, and presence of papillary/micropapillary patterns are notable and support guide-
lines to routine testing for ALK fusions (Lindeman et al. 2018). Although patients with
EML4-ALK fusions are likely to benefit from ALK inhibitor therapy, the response of other
ALK fusion oncoproteins remains to be investigated.
SLMAP encodes a striatin-interacting phosphatase and kinase (STRIPAK) complex with
roles in cell signaling, cell cycle control, cell migration, Golgi assembly, and apoptosis.
Missense mutations in SLMAP have been associated with the pathophysiology of diabetes
and Brugada syndrome (Ishikawa et al. 2012; Upadhyay et al. 2015). Although SLMAP is
not considered an oncogene, growing evidence correlates dysregulation of STRIPAK com-
plexes with human diseases including cancer (Shi et al. 2016). As the genomic landscape ex-
pands, documentation of structural variants in which new and novel genes that associatewith
known drivers are responsive to targeted therapy is essential for patient care.
SUMMARY
This is a case of a 73-yr-old former smoker who had a lung adenocarcinoma that was positive
by ALK IHC and FISH. NGS testing on the RNA revealed a SLMAP-ALK fusion. The patient
has been free of recurrence and/or metastatic disease for 2 yr. Identification of newand novel
fusions with appropriate NGS technologies can provide further biological and clinical in-
sights into ALK-positive lung cancer. It is also helpful in understanding the variable respons-
es to ALK-targeted therapies in patients with NSCLC. Identification of ALK fusion partners,
using NGS, before initiation of therapy, may result in more effective patient management.
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